الصفحة الرئيسية>>Signaling Pathways>> PROTAC>>NH2-PEG2-C2-Boc

NH2-PEG2-C2-Boc

رقم الكتالوجGC61128

NH2-PEG2-C2-Boc عبارة عن رابط PROTAC قائم على PEG يمكن استخدامه في تركيب PROTACsNH2-PEG2-C2-Boc هو أيضًا رابط PEG ADC غير قابل للكسر مكون من وحدتين يستخدم في تخليق اتحادات الأجسام المضادة والأدوية (ADCs)

Products are for research use only. Not for human use. We do not sell to patients.

NH2-PEG2-C2-Boc التركيب الكيميائي

Cas No.: 756525-95-8

الحجم السعر المخزون الكميّة
100mg
22٫00
متوفر
250mg
29٫00
متوفر
500mg
40٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NH2-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. NH2-PEG2-C2-Boc is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[2].

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[2].

[1]. Han X, et al. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. [2]. Joshua D. Thomas, et al. Pyrrolobenzodiazepine antibody conjugates. WO2019126691A1.

مراجعات

Review for NH2-PEG2-C2-Boc

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NH2-PEG2-C2-Boc

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.